Showing results (11-20 of 171) with videos related to
Sort By:
Pageof 18
Physical Review Letters|April 1, 2014
Production of hhjj at the LHCMatthew J Dolan, Christoph Englert, Nicolas Greiner, et al.Advances in Experimental Medicine and Biology|September 9, 2010
Economic considerations in the provision of treatments for rare diseasesChristopher McCabe, Richard Edlin, Jeff RoundInternational Journal of Technology Assessment in Health Care|April 11, 2008
Why licensing authorities need to consider the net value of new drugs in assigning review priorities: addressing the tension between licensing and reimbursementChristopher McCabe, Karl Claxton, Anthony O'HaganPharmacoeconomics|July 24, 2013
Navigating time and uncertainty in health technology appraisal: would a map help?Christopher McCabe, Richard Edlin, Peter HallMedical Decision Making : an International Journal of the Society for Medical Decision Making|August 25, 2016
Determinants of Change in the Cost-effectiveness ThresholdMike Paulden, James O'Mahony, Christopher McCabePharmacoeconomics|November 14, 2009
Weighting must wait: incorporating equity concerns into cost-effectiveness analysis may take longer than expectedAllan Wailoo, Aki Tsuchiya, Christopher McCabeTrends in Cancer|August 29, 2018
Balancing the Economics and Ethics of Personalised OncologyNicola Flaum, Peter Hall, Christopher McCabeNature Reviews. Clinical Oncology|November 14, 2018
Addendum: Low-value approvals and high prices might incentivize ineffective drug developmentVinay Prasad, Christopher McCabe, Sham MailankodyPharmacoeconomics|September 5, 2008
The NICE cost-effectiveness threshold: what it is and what that meansChristopher McCabe, Karl Claxton, Anthony J CulyerPharmacoeconomics|December 13, 2016
Discounting the Recommendations of the Second Panel on Cost-Effectiveness in Health and MedicineMike Paulden, James F O'Mahony, Christopher McCabePageof 18